- Research news
- Published:
Absolute BlyS
Genome Biology volume 2, Article number: spotlight-20010822-01 (2001)
The B-cell cytokine BlyS/BAFF (B-cell activating factor; also referred to as TALL-1, THANK or zTNF4) plays a critical role in B-lymphocyte development. Two receptors for the tumor necrosis factor family of ligands bind to BlyS/BAFF - the B-cell maturation antigen (BCMA) and TAC1. In the August 16 ScienceXpress, two papers from researchers at the Cambridge-based biotechnology company Biogen describe the role of BAFF and its receptors in B-cell function. Thompson et al. identified a third receptor, BAFF-R, on mouse and human B-lymphocytes. They discovered that a mutant mouse line A/WySnJ expressed an aberrant BAFF-R receptor that accounts for its B-cell phenotype (namely, reduction in number of mature peripheral B-cells despite normal bone marrow and peritoneal B1 cells). In an accompanying paper, Schiemann et al. describe the phenotype of mice lacking the BlyS/BAFFgene. The knockout mice had a dramatic loss of follicular and marginal zone B-cells in the spleen and reduced serum antibody levels. The BlyS/BAFF knockout phenotype is similar to that of the A/WySnJ strain, but differs from those of mice lacking BCMA or TAC1. These two studies clearly demonstrate the significance of the Blys/BAFF factor, and its novel receptor BAFF-R, in B-cell development in vivo.
References
ScienceXpress , [http://www.sciencexpress.org]
Biogen , [http://www.biogen.com]
BAFF-R, a Novel TNF Receptor That Specifically Interacts with BAFF, [http://www.sciencemag.org/cgi/content/abstract/1061965v1]
Phenotypic and genetic characterization of a unique B lymphocyte deficiency in strain A/WySnJ mice.
An Essential Role for BAFF in the Normal Development of B Cells Through a BCMA-Independent Pathway, [http://www.sciencemag.org/cgi/content/abstract/1061964v1]
Rights and permissions
About this article
Cite this article
Weitzman, J.B. Absolute BlyS. Genome Biol 2, spotlight-20010822-01 (2001). https://doi.org/10.1186/gb-spotlight-20010822-01
Published:
DOI: https://doi.org/10.1186/gb-spotlight-20010822-01
Keywords
- Marginal Zone
- Biotechnology Company
- Normal Bone Marrow
- Dramatic Loss
- Tumor Necrosis Factor Family